Wasatch Advisors Adds $57M in Novanta Inc. ($NOVT)

Key Points

  • Wasatch Advisors changed its Novanta Inc. ($NOVT) stake by 54.57% last quarter, boosting to 996,645 shares worth $161.68 million.
  • Wall Street's consensus rating on $NOVT is Strong Buy and an average price target of $194.50.
  • $NOVT last traded around $162.22.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Wasatch Advisors increased its position in Novanta Inc. ($NOVT) by 54.57% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 996,645 shares of Novanta Inc. after buying 351,863 shares during the quarter. Wasatch Advisors's holdings in Novanta Inc. were worth $161.68 million as of its most recent filing.

Novanta Inc. Stock Up 14.1%

Shares of Novanta Inc. ($NOVT) traded around $162.22 on Saturday, up 14.1% for the day.

Last price$162.22
Market cap$5.53B
P/E ratio92.54
Forward P/E33.49
Beta1.68
52-week low$98.27
52-week high$176.38
50-day MA$151.93
200-day MA$136.81
Current ratio4.57
Quick ratio3.65
Debt-to-equity0.18

Novanta Inc. Earnings

EPS (ttm)$1.58
Revenue (ttm)$1.03B
Revenue growth10.30%
Net margin6%
Return on equity5.11%
Next earningsNov 3, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$194.50
High target$195
Low target$194
Analysts covering2

About Novanta Inc.

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

ExchangeNasdaqGS
SectorTechnology
IndustryScientific & Technical Instruments
HeadquartersBedford, MA
CEOMr. Matthijs Glastra
Employees3,000

Get Novanta Inc. alerts

New 13F filings, insider trades, and analyst moves on $NOVT, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.